Quick Answer
Xilio Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $137.53 million for the year ending 2025.
- Xilio Therapeutics, Inc. showed an increase of +148.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Xilio Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $141.22 million | Q2 2021: $120.30 million | Q3 2021: $99.77 million | Q1 2022: $176.96 million | Q2 2022: $159.41 million | Q3 2022: $139.14 million | Q1 2023: $93.27 million | Q2 2023: $75.38 million | Q3 2023: $59.77 million | Q1 2024: $33.98 million | Q2 2024: $74.95 million | Q3 2024: $61.26 million | Q1 2025: $89.07 million | Q2 2025: $121.55 million | Q3 2025: $103.76 million.
- Over the full 6 years of available data (2020 to 2025), Xilio Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 614.9%.
- Historical annual values: Fiscal year 2025: $137.53 million | Fiscal year 2024: $55.29 million | Fiscal year 2023: $44.70 million | Fiscal year 2022: $120.39 million | Fiscal year 2021: $198.05 million | Fiscal year 2020: $19.24 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: